Neoadjuvant radiotherapy concurrent with weekly @entity1311 and XXXX and followed by surgery in locally advanced @entity1149 .

@entity1 @entity137 @entity5 @entity3003 @entity2910 @entity1149 @entity1311
Thirty-seven @entity1 were enrolled in a phase II study to evaluate the efficacy and @entity137 of neoadjuvant radiotherapy concurrent with weekly @entity1311 and @entity3003 in locoregionally advanced @entity1149 ( @entity1149 ). The study was also designed to evaluate the operability following concurrent chemoirradiation. The following response rates to chemoirradiation were obtained: complete response (CR) 5 of 37 (13.5%), partial response 14 of 37 (38%), stable disease 12 of 37 (32.5%) and PD 6 of 37 (16%). Twenty @entity1 underwent surgery, and in 19 @entity1 the @entity5 was totally resected. There was pathologic CR in 4 @entity1 . Moderate/severe @entity2910 developed in 16 @entity1 (43%); hematologic @entity137 was mild. There was one case of postoperative mortality. Nine @entity1 are alive without evidence of disease at 5+ to 39+ months. Median survival is 22 months. It is concluded that neoadjuvant radiotherapy concurrent with weekly @entity1311 / @entity3003 is effective and well tolerated in @entity1 and feasible for @entity1 with locally advanced @entity1149 , allowing complete @entity5 resection in 56% of the cases.
